MCOLN3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL333988	0.71	3/20
SCHEMBL493045	0.67	3/20
SCHEMBL281571	0.65	3/20
SCHEMBL494192	0.64	3/20
SCHEMBL77762	0.62	3/20
SCHEMBL79126	0.62	3/20
SCHEMBL334481	0.61	3/20
SCHEMBL463967	0.54	3/20
SCHEMBL463907	0.51	3/20
SCHEMBL567398	0.51	3/20
SCHEMBL125148	0.50	3/20
Hydrochloric Acid (SCHEMBL567326)	0.50	3/20
SCHEMBL587370	0.50	3/20
SCHEMBL693105	0.48	3/20
Alcohol (SCHEMBL282056)	0.47	3/20
SCHEMBL65691	0.46	3/20
Succinimide (SCHEMBL217796)	0.46	3/20
SCHEMBL384730	0.46	3/20
SCHEMBL48288	0.46	3/20
SCHEMBL48870	0.46	3/20

Clinical trials — most relevant to MCOLN3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease	PHASE1/PHASE2	COMPLETED
Safety Study of a Gene Transfer Vector (Rh.10) for Children With Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)	PHASE1	COMPLETED
Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype	EARLY_PHASE1	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Mucolipidosis Type IV Natural History Study	nan	ACTIVE_NOT_RECRUITING
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis	nan	RECRUITING
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes	nan	RECRUITING
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)	nan	COMPLETED
Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment	nan	COMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Myotubular and Centronuclear Myopathy Patient Registry	nan	RECRUITING
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD	nan	ENROLLING_BY_INVITATION
New Strategies of Genetic Study of Patients With Oculocutaneous Albinism	nan	COMPLETED
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital	nan	UNKNOWN
Familial Partial Lipodystrophy Study	nan	COMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS	nan	RECRUITING
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.	nan	COMPLETED
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Evaluation of Limb-Girdle Muscular Dystrophy	nan	COMPLETED
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
Molecular and Genetic Studies of Congenital Myopathies	nan	RECRUITING
Diagnosis of Primary Ciliary Dyskinesia	nan	COMPLETED
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy	nan	COMPLETED
Registry of Unexplained Cardiac Arrest	nan	COMPLETED
for Adipose Tissue DIabetes VAriants (fATDIVA)	nan	COMPLETED
Predisposition Genes in Monogenic Diabetes (DIAMONO)	nan	COMPLETED
Genetic Research of Monogenic Obesity in a Pediatric Cohort With Severe and Early Onset Obesity (GENOBE)	nan	UNKNOWN
Genetic Variations That Increase the Risk for Calcium Kidney Stones: a Family-based Study	nan	COMPLETED
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MCOLN3 binder may also engage these)

Protein	Name	Similarity
F6RG56	—	0.999	F6RG56 →
Q8R4F0	—	0.993	Q8R4F0 →
Q99J21	—	0.971	Q99J21 →
Q60HE8	—	0.965	Q60HE8 →
Q61143	—	0.964	Q61143 →
Q9WTN5	—	0.963	Q9WTN5 →
MCOLN1	Mucolipin-1	0.963	landscape →
Q9ULQ1	—	0.962	Q9ULQ1 →
TRPC6	Short transient receptor potential channel 6	0.961	landscape →
MCOLN2	Mucolipin-2	0.960	landscape →
Q9EQJ0	—	0.960	Q9EQJ0 →
Q8K595	—	0.959	Q8K595 →
Q6GQE1	—	0.957	Q6GQE1 →
Q5RET6	—	0.956	Q5RET6 →
Q9MYW0	—	0.956	Q9MYW0 →
Q6R5J2	—	0.956	Q6R5J2 →
Q5ZMP3	—	0.956	Q5ZMP3 →
Q9JLG4	—	0.956	Q9JLG4 →
Q9NZM6	—	0.955	Q9NZM6 →
Q3TDN0	—	0.954	Q3TDN0 →
Q9BYT9	—	0.954	Q9BYT9 →
Q5U239	—	0.954	Q5U239 →
Q17QL9	—	0.953	Q17QL9 →
A2AHL1	—	0.953	A2AHL1 →
Q9NVA4	—	0.953	Q9NVA4 →
Q4GZT3	—	0.952	Q4GZT3 →
Q98864	—	0.952	Q98864 →
TRPM8	Transient receptor potential cation channel subfamily M member 8	0.951	landscape →
Q9QZ71	—	0.951	Q9QZ71 →
Q9R283	—	0.950	Q9R283 →